Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85874 | 0.97 | HDAC3 (0.44) | HDAC3HDAC1KIF11MEN1KMT2A | |
| SCHEMBL10198580 | 0.96 | SMN1; SMN2 (0.41) | HDAC3HDAC1KIF11MEN1RAB9A | |
| SCHEMBL13057621 | 0.93 | HDAC1 (0.38) | HDAC3HDAC1KIF11NR1H4HDAC8 | |
| SCHEMBL10198583 | 0.93 | HDAC3 (0.41) | HDAC3HDAC1MEN1KMT2A | |
| SCHEMBL85876 | 0.88 | HDAC3 (0.47) | HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL19945148 | 0.87 | HDAC3 (0.42) | HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL85827 | 0.87 | KIF11 (0.41) | KIF11NR1H4MEN1RAB9AKMT2A | |
| SCHEMBL10198591 | 0.85 | HDAC3 (0.45) | HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL85722 | 0.84 | PTGS1 (0.44) | HDAC3HDAC1KIF11NR1H4MEN1 | |
| SCHEMBL19940162 | 0.84 | HDAC3 (0.40) | HDAC3HDAC1MEN1KMT2AHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | INNOVATION PHARMACEUTICALS INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160151314-A1 | Facially Amphiphilic Polymers and Oligomers and Uses Thereof | NATIONAL SCIENCE FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2008-07-24 | — | — | US | disclosed |
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | TLR3, ABHD16A, ANTXR2 | HDAC3 376/4885HDAC1 1308/4885KIF11 4373/4885 |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC1 562/4885KIF11 2152/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC1 562/4885KIF11 2152/4885 |
| US-20160151314-A1 | Facially Amphiphilic Polymers and Oligomers and Uses Thereof | TLR3, ABHD16A, ANTXR2 | HDAC3 376/4885HDAC1 1308/4885KIF11 4373/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | HDAC3 291/4885HDAC1 405/4885KIF11 2804/4885 |
| US-20110124664-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | HDAC3 136/4885HDAC1 156/4885KIF11 3075/4885 |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | HDAC3 136/4885HDAC1 156/4885KIF11 3075/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC1 562/4885KIF11 2152/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | HDAC3 291/4885HDAC1 405/4885KIF11 2804/4885 |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | MUC1, SOST, ALG1 | HDAC3 912/4885HDAC1 1443/4885KIF11 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.